Farmacija d.o.o. Tuzla has developed a novel non-interferon drug for Multiple Sclerosis treatment and other inflammatory and immunomodulatory diseases utilizing two neuropeptides that participate in modulation of immunological processes.
As a combination of two endogenous neuropeptide components, Enkorten modulate immunological processes with analgesia, antipyretic, antioxidant and anti-inflammatory effects without side effects related to steroid and non-steroid anti-inflammatory drugs.

Immunomodulation based on antigens and peptides is targeted toward achieving long term satisfying remission without appearance of toxic side effects characteristic of immunosupressive drugs.

It is based on two approaches:
- blocking of initial activation of antigen recognition of autoreactive T cells,
- down regulation of specific antigenic inflammatory response of T cells through activation of regulatory physiological pathways.

 PRODUCTION AND PATENT - more about >>